← Back to Clinical Trials
Recruiting NCT06865040

NCT06865040 Perioperative Inhaled Therapy in Carcinological Thoracic Surgery in Patients at High Risk of Postoperative Pulmonary Complications

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06865040
Status Recruiting
Phase
Sponsor Centre Hospitalier Universitaire, Amiens
Condition Thoracic Surgery
Study Type INTERVENTIONAL
Enrollment 266 participants
Start Date 2025-07-31
Primary Completion 2028-03

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Formoterol Fumarate 12 mcg (Foradil Aerolizer)Usual treatment

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 266 participants in total. It began in 2025-07-31 with a primary completion date of 2028-03.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The objective of the study is to evaluate, in a clinical trial, the efficacy of peri operative administration of long-acting inhaled ß-2 mimetics on the occurrence of postoperative pulmonary complications

Eligibility Criteria

Inclusion Criteria: * Adult (\>18 years) * Lung cancer eligible for surgical management by lung resection (non-small cell lung carcinoma = NSCLC) by any route * Naïve to long-term inhaled bronchodilator therapy * High risk of post-operative pulmonary complications (Pre-operative FEV1 \< 80%) Exclusion Criteria: * Patient refusal * Pregnancy * Emergency surgery * Patient with a physiological status of WHO IV or ASA ≥ IV * Asthma * Patients treated with long-acting bronchodilators * Severe heart failure (NYHA IV), unstable ischaemic heart disease (angina or recent infarction \< 3 months), obstructive hypertrophic cardiomyopathy, subvalvular aortic stenosis, severe uncontrolled hypertension Recent stroke \< 3 months * High-grade unresponsive conductive disorders or unstable arrhythmia * Thyrotoxicosis, pheochromocytoma * Unbalanced diabetes * Hypersensitivity to ß-2 mimetics or lactose * Current participation in a trial of another drug therapy

Contact & Investigator

Central Contact

THOMAS LEFEBVRE, MD

✉ Lefebvre.Thomas@chu-amiens.fr

📞 33 + 322087889

Frequently Asked Questions

Who can join the NCT06865040 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Thoracic Surgery. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06865040 currently recruiting?

Yes, NCT06865040 is actively recruiting participants. Contact the research team at Lefebvre.Thomas@chu-amiens.fr for enrollment information.

Where is the NCT06865040 trial being conducted?

This trial is being conducted at Amiens, France.

Who is sponsoring the NCT06865040 clinical trial?

NCT06865040 is sponsored by Centre Hospitalier Universitaire, Amiens. The trial plans to enroll 266 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology